19 January 2021
WEEKLY NEWS

ESCMID Position Statement on COVID-19 Vaccination

ESCMID has published a statement addressing the society’s current position on COVID-19 vaccination.

The statement is available in the ESCMID COVID-19 Resource Centre, where you can find many other COVID-related articles, websymposia and guidelines.

ECCMID 2021 Abstract submission is now open!

PUBLIC CONSULTATION OPEN for “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2020”

The draft version of the “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2020” has now entered the Public Consultation Phase.

ESCMID members wishing to comment on the manuscript should write to guidancedocuments@escmid.org indicating their ESCMID membership number.

You will receive the confidential manuscript, along with the comments form for listing feedback and the together with the template to register their comments and the AGREE GLOBAL RATING SCALE form to be completed (More information about the AGREE II tool can be found here).

Please note that by accepting to participate to the Public Consultation Phase, you agree to commit to confidentiality and to respond within the deadline.

Based on the comments received, the ESCMID Executive Committee will decide on whether to grant ESCMID endorsement to this document or not.

The deadline to provide feedback and comments is 1 February 2021.

EMA communication: “Human Medicines Highlights” Newsletter - January 2021 issue

EMA has shared with ESCMID the latest edition of the monthly Newsletter which includes decisions by EMA Scientific Committees and updates on medicines safety.

ESCMID and EMA hope that you will find this useful. You can access the Newsletter by clicking here. Previous editions can also be found on this page.

ESCMID YouTube Channel: Catch highlights of ECCVID!

Have you subscribed to the ESCMID YouTube channel? Over the past weeks several sessions from ECCVID have been uploaded, including keynote lectures and interview sessions.

Visit the ESCMID YouTube channel to view and subscribe!

Article on “The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines”

EMA IS pleased to share with ESCMID an article on “The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines”, published in The Lancet on 13 January.

Conditional marketing authorisation (CMA) is used in EU legislation for emergency situations in response to public health threats to speed up approval and save lives. This article explains in details EMA’s evaluation process that led to the recommendation of the first EU CMA for a COVID-19 vaccine.

Please check EMA’s dedicated webpage on COVID-19 for the latest updates.

CMI highlight: Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance system target bacteria

The health impact of antimicrobial resistance (AMR) has not been included in the Global Burden Disease (GBD) report, as reliable data has been lacking. AMR burden estimates have been derived from models combining incidence and/or prevalence data from national and/or international surveillance systems and mortality estimates from clinical studies. Depending on utilized empirical data, statistical methodology and applied endpoints, the validity and reliability of results can substantially differ.

The systematic review aimed at assessing comprehensiveness, internal and external validity of studies estimating the clinical impact of infections caused by the priority antibiotic resistant pathogens monitored by the WHO Global Antimicrobial Resistance Surveillance System.